Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The combination of capecitabine and temozolomide (CAPTEM) is one of the treatment options for metastatic pancreatic neuroendocrine neoplasms (pNENs). This study aims to evaluate the efficacy of CAPTEM in patients with metastatic intermediate to high-grade pancreatic neuroendocrine tumor (pNET) or carcinoma (pNEC). Methods: This study was conducted retrospectively in a single center. Patients were treated for intermediate to high-grade tumor with 750 mg/m² of capecitabine twice daily from day 1 to 14 and 200 mg/m² of temozolomide once daily from day 10 to 14, repeating twice in a cycle of 28 days. The primary outcomes were durations of overall survival (OS) and progression- free survival (PFS). The secondary outcomes consisted of objective response rate and disease control rate. Results: A total of 12 patients (grade 2 NET in six, grade 3 NET in three, NEC in three patients) who received CAPTEM were included in this study. Patients received a median of five cycles (range, 2 to 46) of CAPTEM. The median dose combined 1,150 mg of capecitabine and 300 mg of temozolomide. The median OS and PFS were 41.2 months (range, 3.2 to 167) and 39.7 months (range, 2.1 to 100), respectively. Patients with NET had longer OS and PFS compared to those of patients with NEC (p = 0.002 and p = 0.028). High Ki-67 proliferative index (> 50%) was significantly associated with poor survival outcomes. Conclusions: CAPTEM showed favorable survival outcomes in patients with metastatic intermediate to high-grade pNENs. Our study supports that CAPTEM may be an effective treatment option for metastatic pNENs.
Abstract
Background/Aims: The combination of capecitabine and temozolomide (CAPTEM) is one of the treatment options for metastatic pancreatic neuroendocrine neoplasms (pNENs). This study aims to evaluate the efficacy of CAPTEM in patients with metastatic intermediate to high-grade pancreatic neuroendocrine tumor (pNET) or carcinoma (pNEC). Methods: This study was conducted retrospectively in a single center. Patients were treated for intermediate to high-grade tumor with 750 mg/m² of capecitabine twice daily from day 1 to 14 and 200 mg/m² of temozolomide once daily from day 10 to 14, repeating twice in a cycle of 28 days. The primary outcomes were durations of overall survival (OS) and progression- free survival (PFS). The secondary outcomes consisted of objective response rate and disease control rate. Results: A total of 12 patients (grade 2 NET in six, grade 3 NET in three, NEC in three patients) who received CAPTEM were included in this study. Patients received a median of five cycles (range, 2 to 46) of CAPTEM. The median dose combined 1,150 mg of capecitabine and 300 mg of temozolomide. The median OS and PFS were 41.2 months (range, 3.2 to 167) and 39.7 months (range, 2.1 to 100), respectively. Patients with NET had longer OS and PFS compared to those of patients with NEC (p = 0.002 and p = 0.028). High Ki-67 proliferative index (> 50%) was significantly associated with poor survival outcomes. Conclusions: CAPTEM showed favorable survival outcomes in patients with metastatic intermediate to high-grade pNENs. Our study supports that CAPTEM may be an effective treatment option for metastatic pNENs.
참고문헌 (12)
- 김연석, "진행성 췌장 신경내분비종양의 최적 치료", 대한췌담도학회지, 21(3), pp.128~137 (2016), 대한췌장담도학회[DOI]
- Clewemar Antonodimitrakis P, "Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors : efficacy, prognostic factors and toxicity", Neuroendocrinology, 103, pp.345~353 (2016)
- Bongiovanni A, "Temozolomide alone or combined with capecitabine for the treatment of metastatic neuroendocrine neoplasia : a"real-world"data analysis", Neuroendocrinology, 111, pp.895~906 (2021)
- de Mestier L, "Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor", Neuroendocrinology, 110, pp.83~91 (2020)
- Strosberg JR, "First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas", Cancer, 117, pp.268~275 (2011)
- Sahu A, "CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors : a single centre experience", J Oncol, 2019, pp.9032753~ (2019)
- Inzani F, "The New World Health Organization classification for pancreatic neuroendocrine neoplasia", Endocrinol Metab Clin North Am, 47, pp.463~470 (2018)
- Halfdanarson TR, "The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors", Pancreas, 49, pp.863~881 (2020)
- Thomas K, "Outcomes of capecitabine and temozolomide(CAPTEM)in advanced neuroendocrine neoplasms(NENs)", Cancers(Basel), 12, pp.206~ (2020)
- Rogowski W, "Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma : retrospective analysis", Endokrynol Pol, 70, pp.313~317 (2019)
- Scarpa A, "Whole-genome landscape of pancreatic neuroendocrine tumours", Nature, 543, pp.65~71 (2017)
- Pea A, "Genetics of pancreatic neuroendocrine tumors : implications for the clinic", Expert Rev Gastroenterol Hepatol, 9, pp.1407~1419 (2015)